Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.63 +1.24 (+2.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Stephens Annual Investment Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
From Veracyte, Inc.
Via Business Wire
News headline image
The Latest Analyst Ratings for Veracyte ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 7, 2023 ↗
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
7 Undervalued Stocks That Analysts Love Right Now ↗
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal. 
Via InvestorPlace
News headline image
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Stock Is Volatile After-Hours - Here's Why ↗
Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier... 
Via Benzinga
News headline image
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
From Veracyte, Inc.
Via Business Wire
News headline image
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? ↗
The genetic test maker is rapidly increasing test volumes. 
Via The Motley Fool
News headline image
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Second Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom ↗
AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider. 
Via InvestorPlace
News headline image
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Market Mixes It Up With A Broad Rally ↗
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.